treated with double antiplatelet therapy for 3 months. Results angiographic success was obtained in all cases. During the hospital there were no death or repeat revascularizations. Non Q-wave myocardial infarction (MI) occurred in 2 (2%) cases in the control arm (p=n.s.). After 1 months, no patient died. One patients in the estrogen arm had a non-Q wave MI 3 days after the procedure and target lesion revascularization with re-PTCA was repeated. All the patients have been scheduled for a 6-month angiographic FU that will be available at the time of presentation.Conclusions Stenting lesions on native coronary arteries with the estrogen coated stents is safe and is associated with high procedural success rate. In hospital course and i-month FU Indicate that estrogen coating stents do not seem to increase the risk of acute or sub-acute stent thrombosis compared to bare metal stent. The efficacy of this therapy in reducing restenosis rate will be assessed when the 6-months angiographic FU results will be available.
Stent-Based Programmable Erodable Polymer Drug Release Systems Are Nontoxic in Porcine Arteries
. Degradation rates were manipulated by altering the PLGA co-monomer ratio and molecular weight. Three low volume PLGA groups with different in-vitrodegradation rates (21 to 180 days), one high volume PLGA group (21 days), and bare metal stent controls were randomly implanted !n the LAD, RCA and superficial femoral arteries (n=40 stents) in a 30 day porcine model (n=12 pigs). Mean coronary injury scores (range: 1.1 to 1.4) did not differ between the five groups. Tissue sections preserving metal and polymer architecture showed small but significant differences in polymer degradation rate (89% vs 78% in fast vs slow groups, pcO.05). Increasing the polymer volume 4-fold slowed the degradation rate to near zero. Blinded histologic scoring showed a neoendothelium, minimal inflammation, foreign body reaction or neointimal fibrin and complete healing in all groups. NO medial necrws or stent strut malapposition was seen. Quantitative angiography and histomorphometry showed no difference in restenosis parameters versus bare metal controls.
6ackground:The ISAR-STEREO-2 tnal has shown that stent strut thickness has a significant Impact on long-term outcome, with lower restenosis rates for thinner strut stents. This effect was seen in a comparison of 2 stents with different design, the thin-strut Guidant RX MultiLink and the thick-strut Cordis 8X Veloccty Small vessels (<2.8mm) have higher restenosis rates, and although some trials in small vessels have shown a significantly lower restenosis rate after stenting compared to PTCA, others have failed to show such benefit, including the ISAR-SMART trial using the MultiLink. Goal of the present analysis was therefore to differentlate the results of ISAR-STEREO-2 with respect to vessel size.
Methods:
All 611 patients randomized I" ISAR-STEREO-2 were included in this analysis. Results for patients with target vessels <2.8mm (n=262) were compared to those with large vessels (Z2.8mm; n=349).
Results:
Baseline clinical and angiographic characteristics did not differ significantly between the 2 groups. The primary end point of ISAR-STEREO-E, angiographic restenosis rate at 6 mo., is illustrated in the graph. mm; diameters 3.0, 3.5, 4.0 mm) was deployed in 267 pabents (age 64 years, 68% male, 23% diabetes) with a single de now native target vessel lesion k 25 mm length) in a multi-center international registry. Anglographic and clinical outcomes for the MULTI-LINK VISIONTM stents are compared with those previously observed for the TETRATM and PENTATM MULTI-LINK@stents.
Conclusiorx
This novel thin strut cobalt chromium MULTI-LINK VISION TM stent demonstrates excellent clinical performance charactenstics with reduced late loss and restenosis compared with prior MULTI-LINK@ stents.
